C-reactive protein and lactate dehydrogenase serum levels potentially predict the response to checkpoint inhibitors in patients with advanced non-small cell lung cancer

被引:6
作者
Wei, Yilun [1 ]
Xu, Jinhe [2 ]
Huang, Xiulian [1 ]
Xie, Siting [1 ]
Lin, Ping [1 ]
Wang, Chenxi [1 ]
Guo, Yuxin [1 ]
Zou, Shumei [2 ]
Zhao, Zhongquan [2 ]
Wen, Wen [2 ]
Song, Yingfang [2 ]
Bao, Zhenming [2 ]
Zhang, Lei [2 ]
Liu, Wei [2 ]
Kong, Wencui [2 ]
Wang, Wenwu [3 ]
He, Baochang [4 ]
Zhang, Shenghang [5 ]
Zhou, Chengzhi [6 ]
Chen, Ying [2 ]
Yu, Zongyang [2 ]
机构
[1] Fujian Med Univ, Fu Zong Clin Med, Fuzhou, Peoples R China
[2] Fujian Med Univ, Xiamen Univ, 900 Hosp Joint Logist Support Force,PLA, Dept Pulm & Crit Care Med,Fuzhou Gen Hosp ,Dongfan, Fuzhou, Peoples R China
[3] Fujian Univ Tradit Chinese Med, Dept Oncol, Affiliated Peoples Hosp 3, Fuzhou, Peoples R China
[4] Fujian Med Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Fujian Prov Key Lab Environm Factors & Canc, Fuzhou, Peoples R China
[5] 900th Hosp Joint Logist Support Force, Inst Clin Lab Med, PLA, Fuzhou, Peoples R China
[6] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis, Guangzhou, Peoples R China
关键词
Non-small cell lung cancer (NSCLC); checkpoint inhibitors; C-reactive protein (CRP); lactic dehydrogenase (LDH); PD-L1; EXPRESSION; ADVERSE EVENTS; PYROPTOSIS; BIOMARKER; AGENTS;
D O I
10.21037/jtd-23-240
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Programmed cell death-ligand 1 (PD-L1) expression and other biomarkers are not completely reliable predictors of the response to checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC). We investigated the value of peripheral serological inflammatory indicators and their combination in predicting the prognosis of patients with advanced NSCLC treated with checkpoint inhibitors.Methods: This study retrospectively analyzed 116 NSCLC patients treated with anti-programmed cell death protein 1 (PD-1)/PD-L1 monoclonal antibodies. Clinical data of the patients were collected before treatment. X-tile plots determined the optimal cut-point for C-reactive protein (CRP) and lactate dehydrogenase (LDH). A survival analysis was performed using the Kaplan-Meier method. Multi-factor Cox regression analysis was used to evaluate the statistically significant factors identified in the univariate analysis.Results: The X-tile plots show the cut-points of CRP and LDH were 8 mg/L and 312 U/L, respectively. Univariate analyses showed high baseline serum LDH and low CRP levels were associated with adverse progression-free survival (PFS). Multivariate analyses indicated that CRP (HR, 0.214, 95% CI: 0.053-0.857, P=0.029) could be a predictive indicator for PFS. In addition, we evaluated the combination of CRP and LDH, and univariate analyses showed that patients with high CRP and low LDH exhibited significantly better PFS than those in the other groups.Conclusions: Baseline levels of serum CRP and LDH have the potential to become a convenient clinical tool to predict response to immunotherapy in advanced non-small cell lung cancer.
引用
收藏
页码:1892 / 1900
页数:9
相关论文
共 39 条
  • [21] Immune-related adverse events with immune checkpoint blockade: a comprehensive review
    Michot, J. M.
    Bigenwald, C.
    Champiat, S.
    Collins, M.
    Carbonnel, F.
    Postel-Vinay, S.
    Berdelou, A.
    Varga, A.
    Bahleda, R.
    Hollebecque, A.
    Massard, C.
    Fuerea, A.
    Ribrag, V.
    Gazzah, A.
    Armand, J. P.
    Amellal, N.
    Angevin, E.
    Noel, N.
    Boutros, C.
    Mateus, C.
    Robert, C.
    Soria, J. C.
    Marabelle, A.
    Lambotte, O.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 54 : 139 - 148
  • [22] Midha A, 2015, AM J CANCER RES, V5, P2892
  • [23] Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study
    Miyawaki, Eriko
    Kenmotsu, Hirotsugu
    Shintani, Yasushi
    Sekine, Ikuo
    Shukuya, Takehito
    Takayama, Koichi
    Inoue, Akira
    Okamoto, Isamu
    Kiura, Katsuyuki
    Takahashi, Kazuhisa
    Yamamoto, Nobuyuki
    Kawaguchi, Tomoya
    Miyaoka, Etsuo
    Yoshino, Ichiro
    Date, Hiroshi
    [J]. BMC CANCER, 2022, 22 (01)
  • [24] Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer
    Moik, Florian
    Zoechbauer-Mueller, Sabine
    Posch, Florian
    Pabinger, Ingrid
    Ay, Cihan
    [J]. CANCERS, 2020, 12 (06) : 1 - 17
  • [25] Ni, 2015, ASIA-PAC J CLIN ONCO, V11, P22
  • [26] Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer
    Oya, Yuko
    Yoshida, Tatsuya
    Kuroda, Hiroaki
    Mikubo, Masashi
    Kondo, Chiaki
    Shimizu, Junichi
    Horio, Yoshitsugu
    Sakao, Yukinori
    Hida, Toyoaki
    Yatabe, Yasushi
    [J]. ONCOTARGET, 2017, 8 (61) : 103117 - 103128
  • [27] Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer
    Ozawa, Yuichi
    Amano, Yusuke
    Kanata, Kei
    Hasegwa, Hirotsugu
    Matsui, Takashi
    Kakutani, Takuya
    Koyauchi, Takafumi
    Tanahashi, Masayuki
    Niwa, Hiroshi
    Yokomura, Koshi
    Suda, Takafumi
    [J]. MEDICAL ONCOLOGY, 2019, 36 (04)
  • [28] PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
    Patel, Sandip Pravin
    Kurzrock, Razelle
    [J]. MOLECULAR CANCER THERAPEUTICS, 2015, 14 (04) : 847 - 856
  • [29] Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data
    Perol, M.
    Felip, E.
    Dafni, U.
    Polito, L.
    Pal, N.
    Tsourti, Z.
    Ton, T. G. N.
    Merritt, D.
    Morris, S.
    Stahel, R.
    Peters, S.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (05) : 511 - 521
  • [30] Cutaneous adverse events caused by immune checkpoint inhibitors
    Quach, Henry T.
    Johnson, Douglas B.
    LeBoeuf, Nicole R.
    Zwerner, Jeffrey P.
    Dewan, Anna K.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (04) : 956 - 966